인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
We aimed to evaluate adherence to oral antineoplastic therapy (OAT) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and its potential relationship with several clinical outcomes. Observational, prospective, multicenter study performed by 6 hospital pharmacists in Spain. The primary outcome was the proportion of treatment adherence as evaluated by pill reconciliation during the 3-month active follow-up period. Those with an adherence > 80% were categorized as adherent. We performed multivariate Cox regression analyses to explore the factors associated with progression-free survival. From December 2019 to November 2022, we recruited 95 evaluable patients. Most of the patients received osimertinib (n = 45, 45.3%) or a first- or second-generation tyrosine kinase inhibitor (n = 23, 34.8%). Eighty-one patients showed greater than 80% adherence (85.3%, 95% CI 78.1% to 92.4%), as evaluated based on pill reconciliation; the mean (SD) adherence to OAT was 94.7% (11.4). According to the univariate analysis, the time to progression from study entry was significantly shorter among patients who were nonadherent than among those who were adherent (median 6.5 months vs. not reached, log-rank test p = 0.006; hazard ratio [HR] 2.619, 95% confidence interval [CI] 1.240–5.532). In the multivariate Cox regression analysis, nonadherence was the single factor associated with progression-free survival. Consistent with previous evidence in this setting, our results suggest that adherence to oral antineoplastic treatment among patients with NSCLC is high. Whether this high rate of adherence translates to better clinical outcomes should be further evaluated in larger samples.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
